Abstract
The majority of breast cancers are estrogen receptor and/or progesterone receptor (ER/PR)-positive and human epidermal growth factor-2 (HER2)-negative. Recent advances have led to improvements in survival outcomes for early-stage ER/PR-positive, HER2-negative breast cancer, although late recurrence remains an ongoing clinical challenge. Systemic therapy for early-stage ER/PR-positive, HER2-negative breast cancer is usually administered postoperatively in the adjuvant setting, although neoadjuvant therapy is used in limited instances. The primary types of systemic therapies used in the management of early-stage ER/PR-positive, HER2-negative breast cancer are endocrine agents and, in some cases, chemotherapy. Emerging data support use of targeted therapies in certain scenarios. Treatment decisions are complex and depend on multiple factors including menopausal status, tumor characteristics, nodal status, comorbidities, and patient preferences. In many cases, multiparameter gene expression assays can help guide decisions about systemic therapy. In this chapter, we will review the current approach to systemic therapy for ER/PR-positive, HER2-negative early-stage breast cancer. We will discuss strategies used to guide selection of therapies, review key trials that have led to the current standard of care, and discuss ongoing unanswered questions and future directions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Bland and Copeland's The Breast: Comprehensive Management of Benign and Malignant Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.